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When ﬁling, searching or analysing clinical data it is
often impossible to know whether a sample has been
taken after the patient has fasted or not. This is a
situation that should not be allowed to continue. Every
dayclinicians arewasting time opening patients records
to look for an indication if the result they are about to
‘ﬁle’ was taken fasted or not. Clinical audit and research
into diabetes, cardiovascular disease and assessment
of renal function are all much less eﬀective when it is
not known whether or not results are based on fasting
samples.
This problem is broader than fasting specimens;
there is a range of pathology tests bettermeasured under
speciﬁc conditions. In primary care the tests best carried
out fasted are: blood glucose and lipid proﬁles. Lab
Tests Online recommend eight hours fasting before
glucose testing and 9–12 hours before serum lipids are
measured.1 Plasma glucose is particularly diﬃcult to
interpret because a fasted specimen only needs to be
over 7.0mmol/l to diagnose diabetes; whereas a random
sample needs to be over 11.1 mmol/l.2 The situation is
further complicated by glucose tolerance tests, where
two readings may arise on the same day. In my research
group we adopt the pragmatic step of processing two
non-zero value plasma glucose tests as a glucose tol-
erance test.
Some urine tests are best done in speciﬁc ways: for
example,midstreamurine tests for infection are thought
to reduce contamination;3 and pregnancy tests may
be more reliable if done ﬁrst thing in the morning.4
Historically, early morning urine (EMU) tests were
used for pregnancy testing though as tests have be-
come more sensitive this has become less necessary.5
Carrying out an ‘EMU’ formany clinicianswas synon-
ymous with doing a pregnancy test.
More recently tests of renal function, speciﬁcally
creatinine, have joined the list of tests best done under
more controlled circumstances. The UK’s National
Institute of Health and Clinical Excellence (NICE)
recommends that when creatinine blood tests are being
carried out to test renal function (or more strictly,
estimate glomerular ﬁltration rate – eGFR) patients
should refrain from eating meat for 12 hours before
the specimen is collected (and that it should be anal-
ysed within 12 hours).6 These stipulations have led the
Editor’s practice to carry out renal function tests as far
as possible alongside fasting lipids in the morning –
when it is less likely that patients will have had a large
protein load and less likely that creatinine specimens
will be left unanalysed overnight.
NICE also recommends that people with impaired
renal function (chronic kidney disease – CKD) should
have a proteinuria test (the albumin–creatinine ratio).
If this is slightly raised it is recommended that this is
repeated in the early morning. Again common sense
dictates that it sensible that this group have all their
blood and urine tests together, fasted, obviating the
need for repeat testing. However, if it is impossible to
tell from the record if it is an earlymorning specimen it
is challenging to audit results.
The correct tagging of specimens and test results in
electronic patient record (EPR) systems should be a
more important issue for informaticians than it ap-
pears to be at present. The status quo is unacceptable
and has a negative eﬀect on patient care by reducing
our ability to use routinely collected data to monitor
the quality of care. Further, if it results in needless
repeat tests it wastes everybody’s time and precious
health resources.
In current quality improvement studies I am involved
in, a combined sample of over 900 000 people had a
prevalence of Type 2 diabetes of 3.4%. These studies
included 27 000 people diagnosed with Type 2 diabetes.
We found 1000 people with Type 2 diabetes on no
treatment, with only an elevated blood glucose measure
to indicate they had diabetes at all. Of this group,
304 people had a plasma glucose of 11.1 mmol/l,
conﬁrming they had diabetes (over 11.1 is diagnostic
regardless of whether fasted or not). The remaining
623 people, roughly six per practice, had a blood glucose
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of at least 7.1 mmol/l but less than 11.1 mmol/l.
Unfortunately between 7.1 mmol/l and 11 mmol/l
we need to know if the patient has fasted or not to
conﬁrm the diagnosis. If this is not ﬂagged in the EPR
people may be recalled unnecessarily to conﬁrm or
refute the diagnosis of diabetes.
The current situation is frustrating because codes
exist to ﬂag these contexts. The Read codes, the term-
inology used in the UK,7 include codes to ﬂag fasting
plasma glucose results or the results of glucose toler-
ance tests; however, these are not operationalised within
the workﬂow which returns laboratory test results to
EPR systems. In my current quality improvement
study we note that around a quarter of the population
have had a plasma glucose blood test. However, of
these quarter of a million glucose results (n = 238 347)
the overwhelming majority were not allocated codes
which indicated if they were taken fasted or not. No
tag was given to 83.1% (n= 198 051). Only aminority,
14.6% (n = 34 829), were labelled with fasting codes,
and 2.3% (n = 5467) were coded as random specimens.
A purist might argue that we need to develop labels
for all alternatives before we move forward – from
fasting blood glucose to day 21 progesterone (a blood
test that is performed on the 21st day of the menstrual
cycle to see whether ovulation has occurred). How-
ever, this editorial proposes that we incorporate just
two into clinical workﬂows: (1) fasting; and (2) ‘early
morning’ for ﬁrst test of the day. An alternative
approach would be to request that NICE insist that
whenever guidance is produced which requires speci-
mens to be taken under particular circumstances, the
necessary code should be operationalised and added
to the laboratory links in such a way that it becomes
part of routine clinical workﬂow. This would allow
relevant clinical data to be properly labelled and un-
necessary test repeats anddiagnosticuncertainty avoided.
Alongside the ambitious National Programme for
IT the informatics community needs to highlight and
address relatively simple issues which would help ensure
that more people with diabetes and other important
clinical conditions are correctly diagnosed andmanaged.
The labelling of results needs to be given greater
priority, alongside other important issues about diabetes
coding and classiﬁcation discussed later in this issue.
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